# Risk Factors of Disease Progression in IgA Nephropathy: A Systematic Review and Meta‐Analysis

**Authors:** Dan Xu, Minjie Zhang, Weiwei Liang, Lijiang Fang, Feifei Ge

PMC · DOI: 10.1002/iid3.70393 · Immunity, Inflammation and Disease · 2026-02-27

## TL;DR

This study identifies key risk and protective factors for disease progression in IgA nephropathy, a kidney disease that can lead to kidney failure.

## Contribution

The study provides a comprehensive meta-analysis of clinical and pathological factors influencing IgA nephropathy progression.

## Key findings

- High blood pressure, elevated serum creatinine, and high LDL cholesterol are significant risk factors for IgA nephropathy progression.
- Pathological features like tubular atrophy and segmental glomerulosclerosis strongly predict disease progression.
- Higher albumin, eGFR, and female sex are protective against disease progression in IgA nephropathy.

## Abstract

IgA nephropathy (IgAN) is an important cause of chronic renal failure, and nearly all patients with IgAN are at risk of developing to end‐stage renal disease (ESRD) during their lifetime. This meta‐analysis aimed to identify and evaluate risk factors associated with the progression of IgAN patients.

Primary studies investigating the risk factors for predicting the progression of IgAN were included in this review. A comprehensive literature search was conducted across multiple electronic databases, including the Chinese Biological Medicine Database (CBM), China National Knowledge Infrastructure (CNKI), Cochrane Library, PubMed, Embase, Web of Science, and WANFANG, up to May 30, 2025. Two independent reviewers screened the literature based on the predefined inclusion and exclusion criteria, extracted the relevant data from the original studies, and assessed the quality of the included studies using the Newcastle‐Ottawa Scale (NOS). Meta‐analysis was performed on at least two studies reporting on a specific outcome, with pooled effect sizes expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). Statistical analysis, including meta‐analysis, subgroup analysis and sensitivity analysis, was conducted using the R software. Publication bias was evaluated using Egger's test in Stata12.0.

A total of 53 studies, comprising 25,517 patients with IgAN, were included in the final analysis. This meta‐analysis identified 10 clinical risk factors significantly associated with IgAN progression, including mean arterial pressure (MAP) (HR = 1.02, 95% CI: 1.01–1.03), diastolic blood pressure (DBP) (HR = 1.03, 95% CI: 1.01–1.05), systolic blood pressure (SBP) (HR = 1.03, 95% CI: 1.01–1.05), serum creatinine (SCr) (HR = 1.04, 95% CI: 1.03–1.06), triglyceride (HR = 1.11, 95% CI: 1.02–1.21), 24‐h urinary protein excretion (UPE) (HR = 1.15, 95% CI: 1.12–1.18), low‐density lipoprotein cholesterol (LDL‐C) (HR = 1.37, 95% CI: 1.18–1.59), male sex (vs. female) (HR = 1.73, 95% CI: 1.16–2.59), complement C4 (C4) (HR = 1.81, 95% CI: 1.06–3.09), and hypertension (HR = 2.53, 95% CI: 1.92–3.33). The pathological features significantly predictive of IgAN progression including crescents (C1/C2) (vs. C0) (HR = 1.57, 95% CI: 1.24–1.99), C2 (vs. C0) (HR = 2.87, 95% CI: 1.65–5.01), endocapillary hypercellularity (E1) (vs. E0) (HR = 1.17, 95% CI: 1.02–1.35), segmental glomerulosclerosis (S1) (vs. S0) (HR = 2.23, 95% CI: 1.78–2.79), and tubular atrophy (T1/T2) (vs. T0) (HR = 5.12, 95% CI: 3.56–7.36), when analyzed individually, T1 (vs. T0) showed an HR = 4.59 (95% CI: 3.24–6.51), and T2 (vs. T0) showed an HR = 16.40 (95% CI: 9.65–27.87). In contrast, C1 (vs. C0) (HR = 1.41, 95% CI: 0.81–2.45) was not significantly associated with progression risk. Protective factors against lgAN progression included higher level of albumin (Alb) (HR = 0.95, 95% CI: 0.93–0.98), estimated glomerular filtration rate (eGFR) (HR = 0.96, 95% CI: 0.95–0.97), hemoglobin (Hb) (HR = 0.98, 95% CI: 0.97–0.99), complement C3 (C3) (HR = 0.97, 95% CI: 0.95–0.99). Additionally, female sex was associated with a lower risk of disease progression, with HR = 0.69 (95% CI: 0.57–0.84) and when compared directly with male HR = 0.55 (95% CI: 0.45–0.67).

This meta‐analysis indicates that MAP, DBP, SBP, SCr, triglyceride, 24‐h UPE, LDL‐C, male sex (vs. female), C4, hypertension, C‐lesions, M‐lesions, S‐lesions, and T‐lesions in Oxford classification are significantly associated with an increased risk of IgAN progression. In contrast, higher levels of Alb, eGFR, Hb, C3, as well as female sex (both as an independent variable and compared with males), are identified as protective factors in patients with IgAN.

## Linked entities

- **Diseases:** IgA nephropathy (MONDO:0005342), end-stage renal disease (MONDO:0004375)

## Full-text entities

- **Genes:** REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, C3 (complement C3) [NCBI Gene 718] {aka AHUS5, ARMD9, ASP, C3a, C3b, CPAMD1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, LOC102723407 (immunoglobulin heavy variable 4-38-2-like) [NCBI Gene 102723407] {aka IGHV4, IGHV4-30, IGHV4-38-2, IGHV4-39, IGHV4-b, IGVH4-39}
- **Diseases:** renal hypertension (MESH:D006977), psoriasis (MESH:D011565), IgA Nephropathy (MESH:D005922), Proteinuria (MESH:D011507), hypoxia (MESH:D000860), Segmental glomerulosclerosis (MESH:C538457), Henoch-Schonlein purpura (MESH:D011695), obesity (MESH:D009765), lesions (MESH:D009059), IgA type nephritis (MESH:D009393), function (MESH:D003291), AKI (MESH:D058186), ankylosing spondylitis (MESH:D013167), kidney failure (MESH:D051437), atrophy (MESH:D001284), CKD (MESH:D051436), liver disease (MESH:D008107), inflammation (MESH:D007249), E-lesions (MESH:D016751), interstitial fibrosis (MESH:D005355), Hyperlipidemia (MESH:D006949), hematuria (MESH:D006417), dyslipidemia (MESH:D050171), NS (MESH:D009404), hyperuricemia (MESH:D033461), diabetic nephropathy (MESH:D003928), hypertriglyceridemia (MESH:D015228), Kidney damage (MESH:D007674), hypercholesterolemia (MESH:D006937), tubular and interstitial lesions (MESH:D017563), T (MESH:D001260), ESRD (MESH:D007676), DBP (MESH:D006337), IgA glomerulonephritis (MESH:D005921), Anemia (MESH:D000740), hypertension (MESH:D006973), sodium retention (MESH:D016055)
- **Chemicals:** cholesterol (MESH:D002784), UA (MESH:D014527), aldosterone (MESH:D000450), triglyceride (MESH:D014280), creatinine (MESH:D003404), lipid (MESH:D008055), SCr (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** rs16955379

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12946928/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12946928/full.md

## References

97 references — full list in the complete paper: https://tomesphere.com/paper/PMC12946928/full.md

---
Source: https://tomesphere.com/paper/PMC12946928